Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials

por Verma, Subodh, Bain, Stephen C., Monk Fries, Tea, Mazer, C. David, Nauck, Michael A., Pratley, Richard E., Rasmussen, Søren, Saevereid, Hans A., Zinman, Bernard, Buse, John B.
Publicado 2019

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results...

por Verma, Subodh, McGuire, Darren K., Bain, Stephen C., Bhatt, Deepak L., Leiter, Lawrence A., Mazer, C. David, Monk Fries, Tea, Pratley, Richard E., Rasmussen, Søren, Vrazic, Hrvoje, Zinman, Bernard, Buse, John B.
Publicado 2020

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

por Buse, John B., Bain, Stephen C., Mann, Johannes F.E., Nauck, Michael A., Nissen, Steven E., Pocock, Stuart, Poulter, Neil R., Pratley, Richard E., Linder, Martin, Monk Fries, Tea, Ørsted, David D., Zinman, Bernard
Publicado 2020